The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Tailoring chemotherapy: R-CHOP dose attenuation in elderly DLBCL
The impact of R-CHOP dose attenuation in elderly patients with diffuse large B-cell lymphoma (DLBCL) is poorly understood. Here, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the study investigating dose intensity between two cohorts containing those who are 70-80 years old vs. those older than 80 years old. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Collins reveals the differing outcomes of dose intensification between these cohorts; leading to potentially practice-changing implications.
